Health Research

Lymphoma (DLBCL): A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Basic Study Information

Are the investigational drugs, durvalumab and lenalidomide a good treatment for DLBCL when combined with the treatment called R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone)?
This study will be testing 2 different investigational drugs called “durvalumab” and “lenalidomide”. These drugs are not yet approved for the treatment of DLBCL. They will be tested in combination with a treatment called R CHOP, which is a combination of 5 drugs (rituximab, cyclophosphamide, vincristine, doxorubicin and prednisone). Currently this is the standard treatment for patients diagnosed with DLBCL who have not yet been treated for this disease.
Cancer Center

Lead Researcher (Principal Investigator)

Patrick Reagan

Study Contact Information

Erin Enfield
(585) 276-4404

Learn More About These Conditions

More information about Lymphoma
More information about Lymphoma